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Case RepoRt
Plasma from a 35-year-old, D– woman was found to have anti-D, 
-C, and -G at 5 weeks’ gestation and again at 8 weeks’ gestation, 
when she presented with a nonviable intrauterine pregnancy. 
The anti-D titer increased with a pattern that suggested it 
was stimulated by the 8-week pregnancy. Six years before this 
admission, the patient’s blood type changed from group O, D+ 
to group O, D– after a bone marrow transplant for aplastic 
anemia. Three years after transplant, the antibody screen 
was negative. After the patient was admitted for the nonviable 
pregnancy, the products of con-ception were found to be D+ by 
DNA testing for RHD. There were no documented transfusions 
or pregnancies during the interval in which anti-D appeared. The 
timing of the alloimmunization was unusual. In a subsequent 
pregnancy, fetal D typing was performed by molecular methods. 
Immunohematology 2012;28:55–9.
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Case Report
A 30-year-old, D+ woman with aplastic anemia 
underwent allogeneic bone marrow transplant (BMT) from 
her HLA-identical, D– brother in December 2003. The 
pretransplant antibody screen (by indirect antiglobulin test 
[IAT]) was negative both in donor and in host. The patient 
received red blood cell (RBC) and platelet transfusions from 
D+ donors before the BMT. RBC transfusions were restricted 
to D– components from the time of conditioning. The patient 
received three units of group O, D+ RBCs on Day –70 and five 
units of group O, D– RBCs between Day –30 and Day +12 
(Table 1). She also received 30 units of single-donor platelets 
(SDP) between Day –70 and Day +12; these included SDPs 
from D+ and D– donors. The conditioning regimen consisted 
of cyclophosphamide and antithymocyte globulin (ATG). The 
patient initially received cyclosporine and methotrexate for 
graft-versus-host (GVH) prophylaxis. On Day +20, she still 
typed as D+ with a negative antibody screen. She required no 
further blood or platelet transfusions after posttransplant Day 
12, and she was tapered off cyclosporine immunosuppression 
9 months after transplant. The patient delivered a healthy, 
D– baby in 2006. During that pregnancy and at delivery, 
the patient typed as D– with a negative antibody screen by 
solid-phase technology. The cord blood typed as group O, D–, 
weak D–, and the father typed as group O, D–.
In January 2009, the patient presented with a pregnancy 
at 5 weeks’ gestation and was found to have anti-D, -C, and 
-G with a titer of 128 against a D+, C+, G+ RBC sample. At 
8 weeks’ gestation, the patient presented with a nonviable 
intrauterine pregnancy, and the anti-D and -C titers were 1024 
and 64, respectively. The patient’s RBCs were negative by the 
direct antiglobulin test (DAT). As the G antigen is expressed 
in the presence of D or C or both, it is highly unlikely that the 
patient and thus the products of conception would express G 
because the D+G– and C+G– phenotypes are extremely rare 
and the D+C+G– phenotype has not been reported. After the 
patient was admitted for the nonviable pregnancy, the products 
of conception were predicted to be D+ by DNA testing for RHD. 
Polymerase chain reaction (PCR)–based assays predicted the 
following phenotypes: mother D+ C+ E– c+ e+ by buccal swab 
and D– C– E– c+ e+ by peripheral blood white blood cells; 
father D– C– E– c+ e+; and conceptus D+ C+ E– c+ e+.
In October 2009, the patient became pregnant for the 
third time. Fetal RHD typing, performed at 18 weeks’ gestation 
from amniotic fluid, predicted a fetal phenotype of D– C– E– 
c+ e+. An analysis of variable number of tandem repeats was 
used to confirm that the results were not affected by maternal 
cell contamination of the amniocyte sample. At that time, the 
anti-D and -C titers were 2048 and 64, respectively.
Materials and Methods
At the hospital laboratory in 2006, the maternal antibody 
screens were performed on an automated analyzer (ABS 2000, 
Immucor Inc., Norcross, GA) using a four-cell screen by solid 
phase technology (Capture-R Ready Screen IV, Immucor 
Inc.). Cord blood typing on the newborn was performed by 
manual tube testing, including weak D testing. In 2009, the 
maternal antibody screen was performed on a newer analyzer 
(Galileo, Immucor Inc.) using a solid phase two-cell screen 
(Capture R Ready Screen II, Immucor Inc.). At the New York 
Blood Center immunohematology laboratory, the anti-D, 
-C, and -G specificities were confirmed using manual tube 
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methods including a sequential adsorption/elution procedure. 
PCR-based assays for RHD, RHCE*C/c, and RHCE*E/e 
were performed on the products of conception, maternal and 
paternal buccal epithelial cells, and maternal blood sample. At 
a reference laboratory during the third pregnancy (early 2010), 
amniotic fluid was used for genomic DNA testing by allele-
specific gene amplification.
Results
Table 1 contains pertinent features of the case in a 
timeline beginning with the BMT and associated transfusions, 
followed by a total of three pregnancies. In summary, Table 1 
depicts the patient’s change in type from D+ to D– after the 
BMT, the negative maternal antibody screen at the time of the 
healthy full-term delivery, the rising anti-D titers during the 
nonviable pregnancy, and the molecular test results from the 
second and third pregnancies. Details of the case history have 
been described earlier in this report.
Table 2 summarizes the results of chimerism testing by 
fluorescence in situ hybridization (FISH) during the year after 
the BMT. The patient’s chimerism results indicated a tiny 
percentage of host-type lymphocytes in the peripheral blood 
a year after transplant. The posttransplant specimens did not 
show mixed-field reactivity in the patient’s RBC typing.
Discussion
The timing of this patient’s alloimmunization to D was 
unusual. If it was caused by the nonviable pregnancy, the 
alloimmunization occurred unusually early in gestation. If it 
was caused by peritransplant exposure to D, it is unusual that 
the antibody did not appear soon after immunosuppression 
was tapered. Posttransplant formations of anti-D are 
uncommon because the donor-related primary immune 
response usually starts about 6 months after the BMT; after 
this period, if recipient bone marrow is 100 percent of donor 
origin, residual D+ recipient RBCs are no longer detectable.1 
Anti-D was identified in one of seven D+ recipients of a 
D– graft, who was also exposed to D+ blood components 
before and after the nonmyeloablative transplant.2 In one 
case, anti-D appeared only when immunosuppression was 
discontinued, 2 years after the BMT.3 Our patient’s plasma 
contained no anti-D 3 years after the BMT, yet anti-D was 
present 6 years after transplant. In one study of D– hosts with 
D– bone marrow donors, the alloimmunization rate by D+ 
blood components was less than 5 percent,4 but some authors 
suggest prophylaxis with intravenous anti-D immunoglobulin 
if D+ platelets must be used.1 Our patient received SDPs 
from both D+ and D– donors, and only D– RBCs were given 
from the start of conditioning for the BMT. There were no 
Table 1. Condensed case description including transplant Day 0 (December 2003), transplant Day +20 (December 2003), full-term 
pregnancy (2006), pregnancy at 5 weeks’ gestation (January 2009), nonviable pregnancy at 8 weeks’ gestation (January 2009), and 
subsequent pregnancy (2010)
Date
Case description 2003 2003 2006  2009  2009 2010
Patient Rh phenotype D+C+E–c+e+ D+ D– D– D–C–E–c+e+ D–
Antibody screen Negative Negative Negative Positive Positive Positive
Anti-D titer — — — 128 1024 2048
Anti-C titer — — — — 64 64
RBC transfusion 3 units, group O D+, 
Day –70
5 units, group O D–, 
Day–30 to Day +12
— — — —
SDP transfusion 30 units (Day–70 to 
Day +12)
— — — — —
Fetal gestational age — — 40 weeks 5 weeks 8 weeks (nonviable) 18 weeks (viable)
Fetal source material — — Cord blood — Products of 
conception
Amniotic fluid
Fetal Rh phenotype — — D– — D+C+E–c+e+ D–C–E–c+e+
RBC = red blood cell, SDP = single-donor platelet.
Table 2. Chimerism results by fluorescence in situ hybridization 
(donor XY, host XX) to show percent engraftment of the bone 
marrow transplantation in the patient (host)
Time Source Cells analyzed Interpretation
Day +30 Marrow 497 XY, 3 XX 99.4% donor, 0.6% host
Day +100 Marrow 495 XY, 5 XX 99% donor, 1% host
Day +365 Blood, unsorted 497 XY, 3 XX 99.4% donor, 0.6% host
Day +365 Blood, T cells 96 XY, 4 XX 96% donor, 4% host
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documented transfusions or pregnancies during the interval 
in which anti-D appeared (between late 2006 and early 2009).
The patient’s chimerism results by FISH showed that her 
engraftment status was almost completely donor, and her RBCs 
typed as donor without mixed-field reaction. RBC chimerism 
was not excluded by more sensitive methods. For example, flow 
cytometry was not performed to look for D+ cells.
Based on the analogous scenario of minor ABO 
mismatched transplants, we would expect this patient to have 
a low risk of alloimmunization for the following reasons: the 
regimen was myeloablative; the source was marrow, not blood 
stem cells; and GVH prophylaxis included both cyclosporine 
and methotrexate. On the other hand, passenger lymphocyte–
mediated hemolysis has been reported to be more common in 
recipients of related donor versus unrelated donor transplants.5 
The conditioning regimen for aplastic anemia is somewhat 
less aggressive than myeloablative regimens for other clinical 
indications and may be considered submyeloablative. Low-
intensity conditioning regimens may leave the host’s antigen-
presenting machinery relatively intact, possibly resulting in 
more potent stimulation of donor memory B cells.6
The maternal anti-D titer increased from the 5-week 
gestation sample to the 8-week gestation sample, suggesting 
the antibody was stimulated by very early pregnancy. Few D– 
women form anti-D that is IgG during their first uncomplicated 
pregnancy. The average rate reported for this is 0.9 percent, 
range 0.3 to 1.9 percent. The risk of D immunization in 
a D– woman is considered to be 1 to 2 percent during a 
pregnancy with a D+ (ABO compatible) fetus, increasing to 
14 to 17 percent during delivery.7 During normal pregnancy, 
transplacental hemorrhage (TPH) can occur as early as at 4 
weeks after fertilization, or 6 weeks after last menstrual period 
(LMP). This is the time when fetal and maternal circulations in 
the placenta have been formed and when the vascularization 
of the villi and the pumping action of the fetal heart begin. At 
this stage of pregnancy, TPH of 0.004 mL has been detected.7
Bergström et al.8 found Rh antigens on the RBCs of a 10-
mm fetus, obtained approximately 38 days after conception 
or 52 days after LMP. The embryo was found in a 47-year-
old woman, with systemic lupus erythematosus (SLE), who 
was undergoing hysterectomy because of a cervical myoma. 
The embryo had a yolk sac and was obtained within intact 
membranes. Microscopic examination of the suspension 
showed almost exclusively nucleated megaloblasts of fetal 
type. The fetal material was found to be D+. Theoretically, 
early abortion could induce anti-D immunization in the D– 
woman. However, there is no evidence in the literature to show 
that spontaneous abortion occurring in the first trimester 
can cause anti-D immunization.7,9 In this patient, the high-
titer, IgG maternal response is unexpected given the 8-week 
gestation without trauma.
The occurrence of anti-D detected in D– individuals 
who have never been exposed to D+ RBCs  through either 
pregnancy or tranfusion is rare. Six cases have been reported 
in the literature. These include a never-pregnant 26-year-
old woman, three women who delivered D– babies, and two 
male patients.9 The authors excluded alloimmunization after 
intravenous drug use with shared needles and administration 
of intravenous immunoglobulin. They suggest other possible 
mechanisms: occult pregnancy followed by undetected 
abortion; the transfer of D+ RBCs from mother to D– fetus 
resulting in alloimmunization (the grandmother theory); 
anamnestic response induced by infection or malignancy; or 
exposure to an unidentified antigen similar to D.
Most recipients of allogeneic hematopoietic stem cell 
transplantation (HSCT) suffer from secondary infertility 
owing to gonadal damage from myeloablative conditioning. 
However, the use of nontotal body irradiation and nonablative 
protocols means that more patients may preserve their fertility. 
Hence, the number of pregnancies involving HSCT recipients 
is increasing.10 Furthermore, in the case of aplastic anemia, the 
post-HSCT outlook for fertility is more favorable than for other 
conditions that require more aggressive regimens. Indeed, a 
1998 study found that at least half of the female patients 
transplanted for aplastic anemia preserved or regained the 
ability to become pregnant.11 For hemolytic disease of the 
fetus and newborn (HDFN), previous pre-HSCT pregnancy 
history cannot predict the risk. This is because both the RBC 
and immune system of the pregnant HSCT recipient have 
switched to those of donor origin. Fortunately, the incidence 
of post-HSCT anti-D is low, and clinical hemolysis is rare.1 Au 
and Leung10 state that it is uncertain whether the anti-D titer 
may increase as a result of anamnestic exposure during post-
HSCT; therefore, frequent monitoring may be prudent.
When the patient in our study became pregnant again in 
October 2009, early fetal genotyping from maternal plasma 
was desired but was limited by the absence of a reliable internal 
control, given that the bone marrow donor was male. Fetal D 
typing from maternal plasma has been performed for several 
years12,13 and is now available in the United States14 using real-
time quantitative PCR. Fetal DNA represents between 3 and 6 
percent of total free DNA in maternal plasma,15 and separating 
fetal DNA from maternal DNA is problematic.16 SRY is a Y 
chromosome–specific sequence that can be amplified to 
confirm that fetal DNA has been successfully detected in the 
case of a male fetus. If the SRY gene is used as the control, 
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cell-free fetal D typing is inconclusive in 14 percent of cases, 
namely those in which there is a D– female fetus detected. In 
these cases, the absence of the RHD gene in the fetus cannot 
be verified because there is no internal control to confirm the 
presence of free fetal DNA in the specimen. Thus, amplification 
of SRY is only effective as a control when the fetus is male.14 But 
in this patient, maternal plasma would likely contain traces of 
male DNA from her bone marrow donor, so SRY could not be 
used as a control. Indeed, Minon et al.17 reported an unusual 
false-positive fetal RHD result using DNA derived from 
maternal plasma from a solid-organ recipient. Tests on DNA 
isolated from the plasma of a D– pregnant woman predicted a 
D+ male fetus, whereas DNA isolated from amniocytes gave a 
D– result. The woman, who had received a kidney transplant 
from a D+ male, delivered a D– girl.
In the current case, cell-free fetal D testing was not 
performed because of the absence of a reliable internal control, 
given that the bone marrow donor was male. Instead, fetal RH 
genotyping was performed on DNA isolated from amniocytes. 
A commercial system in development in the United States, 
which involves mass spectrometry, will include other genes to 
be used as controls.18–20 Tests using other fetal identifiers are 
also in development outside the United States.21
Fetal RBC phenotype may appear to exclude maternal 
contribution in scenarios such as donor egg or maternal host 
of HSCT (Table 3). Finally, this case raised the possibility that 
maternal anti-D might impact early gestational outcomes, 
although no such relationship exists in the literature. In this 
patient, two pregnancies with D– fetuses progressed without 
complication, whereas the pregnancy with a D+ fetus was 
nonviable.
Conclusions
In this case, maternal anti-D alloimmunization was 
detected 6 years after BMT, at the time of an early nonviable 
pregnancy. The 8-week pregnancy may represent a secondary 
alloimmunization event after a primary event of graft immune 
cells responding to residual host RBCs, but the timing is 
unusual. Fetal D typing from maternal plasma is now available 
in the United States using real-time quantitative PCR. Genes 
other than SRY must be used as fetal identifiers to provide a 
reliable internal control for female D– fetuses. In a mother 
who has had a transplant, DNA from the bone marrow donor 
can be amplified. This is particularly problematic when the 
mother’s type has changed from D+ to D–.
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